Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491.

Ishak, Jack

Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491. [electronic resource] - European journal of haematology Jul 2011 - 95; author reply 96-7 p. digital

Publication Type: Letter; Comment

1600-0609

10.1111/j.1600-0609.2011.01624.x doi


Antineoplastic Agents--economics
Boronic Acids--economics
Bortezomib
Cost-Benefit Analysis
Dexamethasone--economics
Humans
Kaplan-Meier Estimate
Lenalidomide
Multiple Myeloma--drug therapy
Pyrazines--economics
Recurrence
Sweden
Thalidomide--analogs & derivatives